CL2007002157A1 - Proteina de fusion que comprende una exendina-4 fusionada a una transferrina; acido nucleico, vector y celula huesped que codifican dicha proteina; composicion farmaceutica que comprende dicha proteina; y uso de la proteina de fusion para tratar diab - Google Patents
Proteina de fusion que comprende una exendina-4 fusionada a una transferrina; acido nucleico, vector y celula huesped que codifican dicha proteina; composicion farmaceutica que comprende dicha proteina; y uso de la proteina de fusion para tratar diabInfo
- Publication number
- CL2007002157A1 CL2007002157A1 CL200702157A CL2007002157A CL2007002157A1 CL 2007002157 A1 CL2007002157 A1 CL 2007002157A1 CL 200702157 A CL200702157 A CL 200702157A CL 2007002157 A CL2007002157 A CL 2007002157A CL 2007002157 A1 CL2007002157 A1 CL 2007002157A1
- Authority
- CL
- Chile
- Prior art keywords
- protein
- fusion protein
- transferrine
- codify
- diab
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title 2
- 108090000623 proteins and genes Proteins 0.000 title 2
- 102000004169 proteins and genes Human genes 0.000 title 2
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 title 1
- 108010011459 Exenatide Proteins 0.000 title 1
- 229960001519 exenatide Drugs 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83258206P | 2006-07-24 | 2006-07-24 | |
| US85747406P | 2006-11-08 | 2006-11-08 | |
| US87496506P | 2006-12-15 | 2006-12-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2007002157A1 true CL2007002157A1 (es) | 2008-02-01 |
Family
ID=38917401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL200702157A CL2007002157A1 (es) | 2006-07-24 | 2007-07-24 | Proteina de fusion que comprende una exendina-4 fusionada a una transferrina; acido nucleico, vector y celula huesped que codifican dicha proteina; composicion farmaceutica que comprende dicha proteina; y uso de la proteina de fusion para tratar diab |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US7867972B2 (es) |
| EP (1) | EP2046826B1 (es) |
| JP (1) | JP5102833B2 (es) |
| KR (1) | KR101193722B1 (es) |
| CN (1) | CN101511868B (es) |
| AR (1) | AR062030A1 (es) |
| AT (1) | ATE524493T1 (es) |
| AU (1) | AU2007278994B2 (es) |
| CA (1) | CA2658654A1 (es) |
| CL (1) | CL2007002157A1 (es) |
| DK (1) | DK2046826T3 (es) |
| ES (1) | ES2371495T3 (es) |
| GT (1) | GT200700059A (es) |
| HK (1) | HK1135112A1 (es) |
| IL (1) | IL196674A (es) |
| MX (1) | MX2009001066A (es) |
| NO (1) | NO20090830L (es) |
| PA (1) | PA8738401A1 (es) |
| PE (1) | PE20080733A1 (es) |
| TW (1) | TW200821327A (es) |
| UY (1) | UY30497A1 (es) |
| WO (1) | WO2008012629A2 (es) |
| ZA (1) | ZA200901280B (es) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4903036B2 (ja) | 2003-01-06 | 2012-03-21 | アンジオケム・インコーポレーテッド | 血液脳関門を通過する担体としてのアプロチニンおよび類似体 |
| PL2360258T3 (pl) | 2005-02-18 | 2015-03-31 | Angiochem Inc | Polipeptydy aprotyniny do transportowania związków przez barierę krew-mózg |
| EP2433653B1 (en) | 2005-07-15 | 2019-06-05 | Angiochem Inc. | Use of aprotinin polypeptides as carriers in pharmaceutical conjugates |
| US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| CA2673085C (en) | 2006-12-12 | 2013-10-15 | Biorexis Pharmaceutical Corporation | Transferrin fusion protein libraries |
| US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| GB0711424D0 (en) * | 2007-06-13 | 2007-07-25 | Novozymes Delta Ltd | Recombinant transferrin mutants |
| WO2010043047A1 (en) * | 2008-10-15 | 2010-04-22 | Angiochem Inc. | Conjugates of glp-1 agonists and uses thereof |
| MX2011005963A (es) | 2008-12-05 | 2011-09-01 | Angiochem Inc | Conjugados de neurotensina o analogos de neurotensina y sus usos. |
| US20110288011A1 (en) * | 2008-12-05 | 2011-11-24 | Jean-Paul Castaigne | Peptide therapeutic conjugates and uses thereof |
| MX2011006685A (es) | 2008-12-17 | 2011-09-27 | Angiochem Inc | Inhibidores de metaloproteinas de matriz de membrana tipo-1 y sus usos. |
| CN102348715B (zh) | 2009-02-03 | 2017-12-08 | 阿穆尼克斯运营公司 | 延伸重组多肽和包含该延伸重组多肽的组合物 |
| JP2012524030A (ja) | 2009-04-20 | 2012-10-11 | アンジオケム インコーポレーテッド | Ａｎｇｉｏｐｅｐ−２アナログにコンジュゲート化した抗癌剤を用いた卵巣癌の治療 |
| NZ596778A (en) | 2009-06-08 | 2013-11-29 | Amunix Operating Inc | Glucose-regulating polypeptides and methods of making and using same |
| US9161988B2 (en) | 2009-07-02 | 2015-10-20 | Angiochem Inc. | Multimeric peptide conjugates and uses thereof |
| US20120148586A1 (en) | 2009-08-27 | 2012-06-14 | Joyce Ching Tsu Chou | Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders |
| KR101259074B1 (ko) * | 2010-11-23 | 2013-04-29 | 서울대학교산학협력단 | 분비신호펩타이드가 연결된 엑센딘-4를 도입한 췌장소도세포 및 이를 이용한 당뇨병 치료방법 |
| CA2833623A1 (en) | 2011-04-20 | 2012-10-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Aav mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity |
| WO2013009545A1 (en) * | 2011-07-08 | 2013-01-17 | Amylin Pharmaceuticals, Inc. | Engineered polypeptides having enhanced duration of action with reduced immunogenicity |
| US10865419B2 (en) * | 2011-10-24 | 2020-12-15 | The Trustees Of The University Of Pennsylvania | Orally administered plastid expressed cholera toxin B subunit-exendin 4 as treatment for type 2 diabetes |
| US20150005233A1 (en) * | 2012-02-08 | 2015-01-01 | Seneb Biosciences, Inc. | Treatment of hypoglycemia |
| CN102618552B (zh) * | 2012-04-01 | 2014-08-20 | 东莞市麦亘生物科技有限公司 | 一种重组艾塞那肽的生产工艺 |
| US20130323221A1 (en) | 2012-05-30 | 2013-12-05 | Biostrategies LC | Plant lectins as carriers of associated drug substances into animal and human cells |
| US10441665B2 (en) | 2012-07-25 | 2019-10-15 | Hanmi Pharm. Co., Ltd. | Liquid formulation of long acting insulinotropic peptide conjugate |
| AR094821A1 (es) | 2012-07-25 | 2015-09-02 | Hanmi Pharm Ind Co Ltd | Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada |
| CN102776148A (zh) * | 2012-08-28 | 2012-11-14 | 中国林业科学研究院资源昆虫研究所 | 一种昆虫细胞生长用培养基 |
| ES2729561T3 (es) | 2012-08-31 | 2019-11-04 | Us Health | Transferencia del gen acuaporina mediada por un virus adenoasociado (aav) para el tratamiento del síndrome de Sjögren |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| CN104902920A (zh) | 2012-12-21 | 2015-09-09 | 赛诺菲 | 作为glp1/gip双重激动剂或glp1/gip/胰高血糖素三重激动剂的毒蜥外泌肽-4衍生物 |
| EP2970399B1 (en) | 2013-03-13 | 2021-11-10 | Emory University | Protein particles comprising disulfide crosslinkers and uses related thereto |
| CN103204944B (zh) * | 2013-03-26 | 2014-05-28 | 江苏健德生物药业有限公司 | 用于治疗糖尿病的长效免疫融合蛋白 |
| CN104513309A (zh) * | 2013-09-26 | 2015-04-15 | 上海亨臻实业有限公司 | 一种蛋白功能结构域铰链肽及其用途 |
| DK3063275T3 (da) | 2013-10-31 | 2019-11-25 | Resolve Therapeutics Llc | Terapeutiske nuklease-albumin-fusioner og fremgangsmåder |
| WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
| EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
| WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
| TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| WO2016025645A1 (en) | 2014-08-12 | 2016-02-18 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker |
| JP6800141B2 (ja) | 2014-08-12 | 2020-12-16 | マサチューセッツ インスティテュート オブ テクノロジー | Ｉｌ−２およびインテグリン結合性ｆｃ融合タンパク質による相乗的な腫瘍処置 |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| DK3307326T3 (da) | 2015-06-15 | 2020-10-19 | Angiochem Inc | Fremgangsmåder til behandling af leptomeningeal karcinomatose |
| AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
| CN106519038B (zh) * | 2015-09-15 | 2019-12-27 | 香港中文大学深圳研究院 | 一种融合蛋白、其生产方法及转基因水稻的生产方法 |
| WO2017181007A1 (en) * | 2016-04-15 | 2017-10-19 | Robert Doyle | Peptide drug improvement using vitamin b12 and haptocorrin binding substrate conjugates |
| CN106397600A (zh) * | 2016-06-24 | 2017-02-15 | 中国药科大学 | 一种具有降血糖活性和透皮能力的重组融合蛋白、编码基因及其应用 |
| HRP20240603T1 (hr) | 2016-07-01 | 2024-07-19 | Resolve Therapeutics, Llc | Optimizirane fuzije binukleaze i postupci njihove upotrebe |
| US10350266B2 (en) | 2017-01-10 | 2019-07-16 | Nodus Therapeutics, Inc. | Method of treating cancer with a multiple integrin binding Fc fusion protein |
| WO2018132516A1 (en) | 2017-01-10 | 2018-07-19 | Nodus Therapeutics | Combination tumor treatment with an integrin-binding-fc fusion protein and immune modulator |
| EP3684811A2 (en) | 2017-08-17 | 2020-07-29 | Massachusetts Institute of Technology | Multiple specificity binders of cxc chemokines and uses thereof |
| CN111315767A (zh) | 2017-08-22 | 2020-06-19 | 萨纳生物有限责任公司 | 可溶性干扰素受体及其用途 |
| CN111448212A (zh) * | 2017-09-14 | 2020-07-24 | 戴纳立制药公司 | 抗trem2抗体及其使用方法 |
| CA3088157A1 (en) * | 2018-01-10 | 2019-07-18 | Denali Therapeutics Inc. | Transferrin receptor-binding polypeptides and uses thereof |
| AU2019219200A1 (en) | 2018-02-12 | 2020-08-06 | BioNTech SE | Treatment using cytokine encoding RNA |
| US11753455B2 (en) | 2018-06-21 | 2023-09-12 | Novo Nordisk A/S | Compounds for treatment of obesity |
| JP7550745B2 (ja) | 2018-07-24 | 2024-09-13 | バイオエヌテック エスエー | Ｉｌ２アゴニスト |
| JP7557882B2 (ja) | 2018-09-28 | 2024-09-30 | マサチューセッツ インスティテュート オブ テクノロジー | コラーゲンに局在化される免疫調節分子およびその方法 |
| SG11202106686PA (en) | 2019-01-04 | 2021-07-29 | Resolve Therapeutics Llc | Treatment of sjogren's disease with nuclease fusion proteins |
| WO2020146807A1 (en) * | 2019-01-10 | 2020-07-16 | Precision Biosciences, Inc. | Genetically-modified cells comprising a modified transferrin gene |
| WO2020154032A1 (en) | 2019-01-23 | 2020-07-30 | Massachusetts Institute Of Technology | Combination immunotherapy dosing regimen for immune checkpoint blockade |
| CA3129100A1 (en) | 2019-02-08 | 2020-08-13 | Biontech Cell & Gene Therapies Gmbh | Treatment involving car-engineered t cells and cytokines |
| BR112021016962A2 (pt) | 2019-03-18 | 2021-11-23 | Biontech Cell & Gene Therapies Gmbh | Variantes do receptor de interleucina-2 (il2r) e da interleucina-2 (il2) para ativação específica de células efetoras imunes |
| WO2020200481A1 (en) | 2019-04-05 | 2020-10-08 | Biontech Rna Pharmaceuticals Gmbh | Treatment involving interleukin-2 (il2) and interferon (ifn) |
| TW202115105A (zh) | 2019-06-24 | 2021-04-16 | 德商拜恩迪克Ｒｎａ製藥有限公司 | Ｉｌ２激動劑 |
| WO2021058091A1 (en) | 2019-09-24 | 2021-04-01 | Biontech Rna Pharmaceuticals Gmbh | Treatment involving therapeutic antibody and interleukin-2 (il2) |
| WO2021129927A1 (en) | 2019-12-23 | 2021-07-01 | Biontech Cell & Gene Therapies Gmbh | Treatment with immune effector cells engineered to express an antigen receptor |
| WO2021129945A1 (en) | 2019-12-27 | 2021-07-01 | Biontech Cell & Gene Therapies Gmbh | In vitro and in vivo gene delivery to immune effector cells using nanoparticles functionalized with designed ankyrin repeat proteins (darpins) |
| CA3171370A1 (en) | 2020-03-16 | 2021-09-23 | Ugur Sahin | Antigen-specific t cell receptors and t cell epitopes |
| WO2021197589A1 (en) | 2020-03-31 | 2021-10-07 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination |
| EP4171614A1 (en) | 2020-06-29 | 2023-05-03 | Resolve Therapeutics, LLC | Treatment of sjogren's syndrome with nuclease fusion proteins |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022218891A2 (en) | 2021-04-12 | 2022-10-20 | BioNTech SE | Rna compositions comprising a buffer substance and methods for preparing, storing and using the same |
| EP4326317A1 (en) | 2021-04-20 | 2024-02-28 | BioNTech SE | Virus vaccine |
| WO2022261186A1 (en) * | 2021-06-08 | 2022-12-15 | University Of Georgia Research Foundation, Inc. | Nanoparticles for preventing peri/post-menopausal bone loss and/or obesity |
| WO2023051926A1 (en) | 2021-09-30 | 2023-04-06 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists |
| CA3235180A1 (en) | 2021-10-21 | 2023-04-27 | BioNTech SE | Coronavirus vaccine |
| WO2023067193A2 (en) | 2021-10-22 | 2023-04-27 | BioNTech SE | Compositions for administration of different doses of rna |
| WO2023083434A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Rna encoding peptidoglycan hydrolase and use thereof for treating bacterial infection |
| WO2023126053A1 (en) | 2021-12-28 | 2023-07-06 | BioNTech SE | Lipid-based formulations for administration of rna |
| WO2023165681A1 (en) | 2022-03-01 | 2023-09-07 | BioNTech SE | Rna lipid nanoparticles (lnps) comprising a polyoxazoline and/or polyoxazine polymer |
| WO2023193892A1 (en) | 2022-04-05 | 2023-10-12 | BioNTech SE | Nucleic acid compositions comprising an inorganic polyphosphate and methods for preparing, storing and using the same |
| US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
| WO2024017479A1 (en) | 2022-07-21 | 2024-01-25 | BioNTech SE | Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production |
| WO2024028325A1 (en) | 2022-08-01 | 2024-02-08 | BioNTech SE | Nucleic acid compositions comprising amphiphilic oligo ethylene glycol (oeg)-conjugated compounds and methods of using such compounds and compositions |
| WO2024028445A1 (en) | 2022-08-03 | 2024-02-08 | BioNTech SE | Rna for preventing or treating tuberculosis |
| WO2024027910A1 (en) | 2022-08-03 | 2024-02-08 | BioNTech SE | Rna for preventing or treating tuberculosis |
| WO2024153324A1 (en) | 2023-01-18 | 2024-07-25 | BioNTech SE | Rna formulations for pharmaceutical use |
Family Cites Families (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4289689A (en) | 1980-03-14 | 1981-09-15 | Hoffmann-La Roche Inc. | Preparation of homogeneous human fibroblast interferon |
| DE3273787D1 (en) | 1981-02-04 | 1986-11-20 | Japan Found Cancer | Human interferon-beta gene |
| US4599311A (en) | 1982-08-13 | 1986-07-08 | Kawasaki Glenn H | Glycolytic promotersfor regulated protein expression: protease inhibitor |
| US4816449A (en) | 1984-08-09 | 1989-03-28 | Immunetech Pharmaceuticals | Immunotherapeutic anti-inflammatory peptide agents |
| AU600885B2 (en) | 1984-05-25 | 1990-08-30 | Zymogenetics Inc. | Stable DNA constructs |
| CH0229046H1 (de) | 1985-03-30 | 1998-07-15 | Stuart Alan Kauffman | Method for obtaining dna, rna, peptides, polypeptinique. des or proteins by means of a dna recombinant tech |
| US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
| US5026651A (en) | 1985-04-25 | 1991-06-25 | Board Of Regents, The University Of Texas System | Methods and compositions for the production of human transferrin |
| US5262177A (en) | 1986-02-07 | 1993-11-16 | Oncogen | Recombinant viruses encoding the human melanoma-associated antigen |
| GB8620926D0 (en) | 1986-08-29 | 1986-10-08 | Delta Biotechnology Ltd | Yeast promoter |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| HU213344B (en) | 1987-04-09 | 1997-05-28 | Delta Biotechnology Ltd | Process for producing of stable dezintegrating plasmid-vectors |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| NZ226414A (en) | 1987-10-02 | 1992-07-28 | Genentech Inc | Cd4 peptide adhesion variants and their preparation and use |
| GB8726953D0 (en) | 1987-11-18 | 1987-12-23 | Delta Biotechnology Ltd | Yeast expression system |
| US6018026A (en) | 1988-01-22 | 2000-01-25 | Zymogenetics, Inc. | Biologically active dimerized and multimerized polypeptide fusions |
| EP0387319B1 (en) | 1988-07-23 | 1996-03-06 | Delta Biotechnology Limited | Secretory leader sequences |
| US5260202A (en) | 1988-09-07 | 1993-11-09 | Delta Biotechnology Limited | Fermentation method |
| GB8820951D0 (en) | 1988-09-07 | 1988-10-05 | Delta Biotechnology Ltd | Fermentation method |
| US5571691A (en) | 1989-05-05 | 1996-11-05 | Baylor College Of Medicine | Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms |
| AU648505B2 (en) | 1989-05-19 | 1994-04-28 | Amgen, Inc. | Metalloproteinase inhibitor |
| GB8927480D0 (en) | 1989-12-05 | 1990-02-07 | Delta Biotechnology Ltd | Mutant fungal strain detection and new promoter |
| EP0413662A3 (en) | 1989-08-15 | 1991-10-23 | Ciba-Geigy Ag | Polyaryleneethers |
| US5672683A (en) | 1989-09-07 | 1997-09-30 | Alkermes, Inc. | Transferrin neuropharmaceutical agent fusion protein |
| US5977307A (en) | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
| US5667986A (en) | 1989-10-18 | 1997-09-16 | Delta Biotechnology Limited | Yeast promoter for expressing heterologous polypeptides |
| GB8923521D0 (en) | 1989-10-18 | 1989-12-06 | Delta Biotechnology Ltd | Yeast promoter |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5545618A (en) | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
| US6066469A (en) | 1990-03-08 | 2000-05-23 | Ferro Dynamics, Inc. | Cloning, expression, and uses of human lactoferrin |
| US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
| US5986067A (en) | 1991-02-08 | 1999-11-16 | The University Of Vermont And State Agricultural College | Recombinant transferrins, transferrin half-molecules and mutants thereof |
| US6825037B1 (en) | 1991-02-08 | 2004-11-30 | University Of Vermont | Recombinant transferrins, transferrin half-molecules and mutants thereof |
| US5656272A (en) | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
| EP0603187A4 (en) | 1991-05-31 | 1995-08-30 | Us Health | Human lactoferrin. |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| ZA932568B (en) | 1992-04-24 | 1993-11-12 | Baylor College Midecine A Non | Production of recombinant human lactoferrin |
| DE4244915C2 (de) | 1992-08-14 | 1998-12-03 | Widmar Prof Dr Tanner | DNA-Moleküle codierend Proteine, die an der O-Glykosylierung von Proteinen beteiligt sind |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| EP0599303A3 (en) | 1992-11-27 | 1998-07-29 | Takeda Chemical Industries, Ltd. | Peptide conjugate |
| US5547871A (en) | 1993-01-25 | 1996-08-20 | American Cyanamid Company | Heterologous signal sequences for secretion of insect controlling proteins |
| US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| US5464933A (en) | 1993-06-07 | 1995-11-07 | Duke University | Synthetic peptide inhibitors of HIV transmission |
| US5840707A (en) | 1993-10-04 | 1998-11-24 | Albany Medical College | Stabilizing and delivery means of biological molecules |
| GB9404270D0 (en) | 1994-03-05 | 1994-04-20 | Delta Biotechnology Ltd | Yeast strains and modified albumins |
| GB9411356D0 (en) | 1994-06-07 | 1994-07-27 | Delta Biotechnology Ltd | Yeast strains |
| US6524557B1 (en) | 1994-12-22 | 2003-02-25 | Astrazeneca Ab | Aerosol formulations of peptides and proteins |
| US5843882A (en) | 1995-04-27 | 1998-12-01 | The United States Of America As Represented By The Department Of Health And Human Services | Antiviral proteins and peptides |
| US5817789A (en) | 1995-06-06 | 1998-10-06 | Transkaryotic Therapies, Inc. | Chimeric proteins for use in transport of a selected substance into cells |
| US7285526B2 (en) | 1995-07-14 | 2007-10-23 | Meiogen Biotechnology Corporation | Interferon antagonists useful for the treatment of interferon related diseases |
| US5925351A (en) | 1995-07-21 | 1999-07-20 | Biogen, Inc. | Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease |
| US5849293A (en) | 1996-01-11 | 1998-12-15 | Cornell Research Foundation, Inc. | Use of human transferrin in controlling insulin levels |
| DK0889949T3 (da) | 1996-03-13 | 2003-09-22 | Delta Biotechnology Ltd | Fermenteringskontrol |
| ES2359031T3 (es) | 1996-08-08 | 2011-05-17 | Amylin Pharmaceuticals, Inc. | Composición farmacéutica que comprende un péptido de exendina-4. |
| US6458924B2 (en) | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| US7235627B2 (en) | 1996-08-30 | 2007-06-26 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
| ATE366584T1 (de) | 1996-11-12 | 2007-08-15 | Novo Nordisk As | Verwendung von glp-1 peptiden |
| JP4798814B2 (ja) | 1997-01-07 | 2011-10-19 | アミリン・ファーマシューティカルズ，インコーポレイテッド | 食物摂取低減用のエキセンジンおよびそのアゴニストの使用 |
| US6723530B1 (en) | 1997-02-05 | 2004-04-20 | Amylin Pharmaceuticals, Inc. | Polynucleotides encoding proexendin, and methods and uses thereof |
| RU2218407C2 (ru) | 1997-04-16 | 2003-12-10 | Юниджен Лэбораториз Инк. | Прямая экспрессия пептидов в культуральные среды |
| GB9713412D0 (en) | 1997-06-26 | 1997-08-27 | Delta Biotechnology Ltd | Improved protein expression strains |
| CA2304642C (en) | 1997-09-26 | 2014-11-18 | Athersys, Inc. | Expression of endogenous genes by non-homologous recombination of a vector construct with cellular dna |
| KR100627590B1 (ko) | 1998-01-30 | 2006-09-25 | 다이이치 아스비오파마 가부시키가이샤 | 보조 펩타이드를 사용하는 펩타이드의 제조방법 |
| EP1062240B1 (en) | 1998-02-27 | 2010-04-28 | Novo Nordisk A/S | N-terminally modified glp-1 derivatives |
| CA2321026A1 (en) | 1998-03-09 | 1999-09-16 | Zealand Pharmaceuticals A/S | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| US6998387B1 (en) | 1998-03-19 | 2006-02-14 | Amylin Pharmaceuticals, Inc. | Human appetite control by glucagon-like peptide receptor binding compounds |
| US6258782B1 (en) | 1998-05-20 | 2001-07-10 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
| GB9902000D0 (en) | 1999-01-30 | 1999-03-17 | Delta Biotechnology Ltd | Process |
| ES2209885T3 (es) | 1999-05-17 | 2004-07-01 | Conjuchem, Inc. | Peptidos insulinotropicos de larga duracion. |
| WO2000069917A1 (fr) * | 1999-05-18 | 2000-11-23 | Maruho Kabushikikaisha | Compositions medicinales destinees a inhiber le systeme kallikreine-kinine ou la phospholipase a¿2? |
| US20030235884A1 (en) | 1999-06-15 | 2003-12-25 | Cummings Richard D. | Polynucleotides encoding core 1 beta3-galactosyl transferase and methods of use thereof |
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| JP2003514532A (ja) | 1999-11-19 | 2003-04-22 | トランスカーヨティック セラピーズ インコーポレイテッド | 生成物の産生量を最適化するための核酸構築体 |
| CA2395525A1 (en) | 1999-12-23 | 2001-06-28 | Human Genome Sciences, Inc. | Transferrin polynucleotides, polypeptides, and antibodies |
| US6380362B1 (en) | 1999-12-23 | 2002-04-30 | Genesis Research & Development Corporation Ltd. | Polynucleotides, polypeptides expressed by the polynucleotides and methods for their use |
| US6420346B1 (en) | 2000-02-07 | 2002-07-16 | Rappaport Family Institute For Research In The Medical Sciences | Polynucleotides encoding MIP-1α, MCP-1, MIP-1β, Rantes and TNF-α, and methods for treating rheumatoid arthritis |
| CA2405557C (en) | 2000-04-12 | 2013-09-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| DK1317479T3 (da) | 2000-09-06 | 2009-11-23 | Aventis Pharma Sa | Fremgangsmåder og sammensætninger for sygdomme, der er associeret med amyloidosis |
| CZ306180B6 (cs) | 2000-12-07 | 2016-09-14 | Eli Lilly And Company | GLP-1 fúzní proteiny |
| CN1363654A (zh) | 2001-07-19 | 2002-08-14 | 上海华谊生物技术有限公司 | 生产促胰岛素分泌肽glp－1(7－36)的基因工程菌以及生产glp－1(7－36)的方法 |
| US20030226155A1 (en) | 2001-08-30 | 2003-12-04 | Biorexis Pharmaceutical Corporation | Modified transferrin-antibody fusion proteins |
| US7176278B2 (en) | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
| MXPA04001804A (es) | 2001-08-30 | 2005-03-07 | Biorexis Pharmaceutical Corp | Proteinas de fusion de transferrina modificada. |
| US20030232761A1 (en) | 2002-03-28 | 2003-12-18 | Hinke Simon A. | Novel analogues of glucose-dependent insulinotropic polypeptide |
| US20060130158A1 (en) | 2002-08-30 | 2006-06-15 | Turner Andrew J | Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains |
| AU2003270009A1 (en) * | 2002-08-30 | 2004-03-19 | Biorexis Pharmaceutical Corporation | Oral delivery of modified transferrin fusion proteins |
| DE60330680D1 (de) | 2002-08-30 | 2010-02-04 | Biorexis Pharmaceutical Corp | Transferrin-fusionsproteinbibliotheken |
| US20060105387A1 (en) | 2002-08-30 | 2006-05-18 | Prior Christopher P | Transferrin fusion proteins libraries |
| US7186692B2 (en) | 2002-12-17 | 2007-03-06 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity |
| AU2003299722A1 (en) | 2002-12-17 | 2004-07-14 | Mdrna, Inc. | Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity |
| US20070060512A1 (en) | 2003-03-04 | 2007-03-15 | Homayoun Sadeghi | Dipeptidyl-peptidase protected protein |
| WO2004078777A2 (en) | 2003-03-04 | 2004-09-16 | Biorexis Pharmaceutical Corporation | Dipeptidyl-peptidase protected proteins |
| AU2004241242A1 (en) | 2003-05-14 | 2004-12-02 | Emisphere Technologies, Inc. | Compositions for delivering peptide YY and PYY agonists |
| EP1631308B1 (en) | 2003-05-30 | 2013-07-31 | Amylin Pharmaceuticals, LLC | Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins |
| US20060205037A1 (en) | 2003-08-28 | 2006-09-14 | Homayoun Sadeghi | Modified transferrin fusion proteins |
| JP2007512001A (ja) | 2003-08-28 | 2007-05-17 | バイオレクシス ファーマシューティカル コーポレイション | Ｅｐｏミメティックペプチドおよび融合タンパク質 |
| GB0329681D0 (en) | 2003-12-23 | 2004-01-28 | Delta Biotechnology Ltd | Gene expression technique |
| WO2006017688A2 (en) * | 2004-08-03 | 2006-02-16 | Biorexis Pharmaceutical Corporation | Combination therapy using transferrin fusion proteins comprising glp-1 |
| WO2006049983A2 (en) | 2004-10-27 | 2006-05-11 | Biorexis Pharmaceutical Corporation | Peptide yy modified transferrin fusion proteins |
| JP2008531059A (ja) * | 2005-03-04 | 2008-08-14 | バイオレクシス ファーマシューティカル コーポレーション | 改変トランスフェリン融合タンパク質 |
-
2007
- 2007-07-13 KR KR1020097003679A patent/KR101193722B1/ko not_active IP Right Cessation
- 2007-07-13 WO PCT/IB2007/002047 patent/WO2008012629A2/en active Application Filing
- 2007-07-13 ES ES07789496T patent/ES2371495T3/es active Active
- 2007-07-13 EP EP07789496A patent/EP2046826B1/en not_active Not-in-force
- 2007-07-13 AU AU2007278994A patent/AU2007278994B2/en not_active Ceased
- 2007-07-13 JP JP2009521363A patent/JP5102833B2/ja not_active Expired - Fee Related
- 2007-07-13 CN CN2007800336434A patent/CN101511868B/zh not_active Expired - Fee Related
- 2007-07-13 DK DK07789496.2T patent/DK2046826T3/da active
- 2007-07-13 AT AT07789496T patent/ATE524493T1/de not_active IP Right Cessation
- 2007-07-13 CA CA002658654A patent/CA2658654A1/en not_active Abandoned
- 2007-07-13 MX MX2009001066A patent/MX2009001066A/es active IP Right Grant
- 2007-07-23 TW TW096126804A patent/TW200821327A/zh unknown
- 2007-07-23 GT GT200700059A patent/GT200700059A/es unknown
- 2007-07-23 PE PE2007000955A patent/PE20080733A1/es not_active Application Discontinuation
- 2007-07-23 AR ARP070103267A patent/AR062030A1/es not_active Application Discontinuation
- 2007-07-23 PA PA20078738401A patent/PA8738401A1/es unknown
- 2007-07-23 UY UY30497A patent/UY30497A1/es not_active Application Discontinuation
- 2007-07-24 CL CL200702157A patent/CL2007002157A1/es unknown
- 2007-07-24 US US11/782,030 patent/US7867972B2/en not_active Expired - Fee Related
-
2009
- 2009-01-22 IL IL196674A patent/IL196674A/en not_active IP Right Cessation
- 2009-02-23 ZA ZA2009/01280A patent/ZA200901280B/en unknown
- 2009-02-23 NO NO20090830A patent/NO20090830L/no not_active Application Discontinuation
- 2009-12-24 HK HK09112164.6A patent/HK1135112A1/xx not_active IP Right Cessation
-
2010
- 2010-11-30 US US12/956,623 patent/US8158579B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| PE20080733A1 (es) | 2008-06-14 |
| GT200700059A (es) | 2008-07-09 |
| ATE524493T1 (de) | 2011-09-15 |
| ZA200901280B (en) | 2010-02-24 |
| HK1135112A1 (en) | 2010-05-28 |
| US7867972B2 (en) | 2011-01-11 |
| CN101511868B (zh) | 2013-03-06 |
| ES2371495T3 (es) | 2012-01-03 |
| EP2046826B1 (en) | 2011-09-14 |
| KR101193722B1 (ko) | 2013-01-11 |
| US20110245178A1 (en) | 2011-10-06 |
| IL196674A0 (en) | 2011-08-01 |
| TW200821327A (en) | 2008-05-16 |
| CN101511868A (zh) | 2009-08-19 |
| US8158579B2 (en) | 2012-04-17 |
| JP2009544301A (ja) | 2009-12-17 |
| WO2008012629A2 (en) | 2008-01-31 |
| WO2008012629A3 (en) | 2008-05-08 |
| AU2007278994A1 (en) | 2008-01-31 |
| JP5102833B2 (ja) | 2012-12-19 |
| EP2046826A2 (en) | 2009-04-15 |
| AR062030A1 (es) | 2008-08-10 |
| PA8738401A1 (es) | 2009-02-09 |
| UY30497A1 (es) | 2008-02-29 |
| US20090239795A1 (en) | 2009-09-24 |
| AU2007278994B2 (en) | 2013-08-15 |
| NO20090830L (no) | 2009-03-02 |
| KR20090033906A (ko) | 2009-04-06 |
| IL196674A (en) | 2014-02-27 |
| CA2658654A1 (en) | 2008-01-31 |
| MX2009001066A (es) | 2009-02-05 |
| DK2046826T3 (da) | 2011-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2007002157A1 (es) | Proteina de fusion que comprende una exendina-4 fusionada a una transferrina; acido nucleico, vector y celula huesped que codifican dicha proteina; composicion farmaceutica que comprende dicha proteina; y uso de la proteina de fusion para tratar diab | |
| CL2008000460A1 (es) | Proteina de fusion que comprende un polipeptido inmunoglobulina; acido nucleico que la codifica; vector y celula huesped; metodo de produccion; composicion que la comprende; y su uso para tratar un trastorno en un sujeto. | |
| EP3034514A4 (en) | Antibody specifically binding to glp-1r and fusion protein thereof with glp-1 | |
| ZA201308465B (en) | Modified biotin-binding protein fusion proteins thereof and applications | |
| CL2015000379A1 (es) | Proteína de fusión que comprende un agonista de glp-1r, fgf-21 o un compuesto mimético y un conector; composición farmacéutica que la comprende; ácido nucleico que la codifica; vector; célula huésped; método de preparación; y uso para tratar enfermedad cardiovascular, diabetes mellitus y/o síndrome metabólico. | |
| CL2009000459A1 (es) | Anticuerpo se une a la proteina rgm a; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; construccion de anticuerpos que comprende dicha proteina; conjugado de anticuerpos que comprende a la construccion; uso. | |
| DK2007884T3 (da) | Cellulasefusionsproteiner og deres anvendelse | |
| CL2009000166A1 (es) | Polipeptido de fusion que comprende un subdominio de la proteina klotho y el factor de crecimiento de fibroblastos; composicion farmaceutica que contiene el polipeptido; acido nucleico; vector y celula huesped que lo contiene; uso de esta composicion para tratar condiciones mediadas por el envejecimiento. | |
| BRPI0918947A2 (pt) | proteína de fusão de anticorpo | |
| CL2013002361A1 (es) | Metodo para medir actividad de células natural killer (nk); kit para medir dicha actividad; proteína de fusión; composicion para activar células nk; polipéptido, oligonucleótido, vector y célula hospedera que comprenden la proteína; | |
| CL2011002756A1 (es) | Anticuerpo que se enlaza a la proteina del complemento c3b humana o de cinomolgo; composicion farmaceutica, acido nucleico, vector y celula huesped que comprenden dicho anticuerpo; uso para tratar degeneracion macular relacionada con la edad. | |
| CL2008000664A1 (es) | Proteina aislada que comprende un polipeptido del receptor iib de una variante de activina; acido nucleico aislado; vector recombinante que comprende dicho acido nucleico; celula huesped; composicion farmaceutica que comprende dicha proteina; uso de | |
| CL2013001625A1 (es) | Proteina de union que se une especificamente a tnf-alfa; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar una enfermedad o trastorno asociado a tnf-alfa. | |
| CL2014002166A1 (es) | Proteína de fusión de factor viii recombinante que comprende al polipéptido recombinante extendido xten; composición farmacéutica que la comprende; ácido nucleico que la codifica; vector; célula huésped; método de producción; y uso para tratar una coagulopatía, tal como hemofilia. | |
| BRPI0916964A2 (pt) | polipetídeo, anticorpo, ácido nucléico, vetor, célula hospedeira, método para produzir um polipeptídeo, composição e uso do polipeptídeo | |
| CL2011002768A1 (es) | Polipéptido mutante fgf21; ácido nucleico que lo codifica; vector; célula huésped; composición farmacéutica que lo comprende; y su uso para tratar un trastorno metabólico. | |
| CU23869B1 (es) | Anticuerpos anti-esclerostina y proteínas funcionales | |
| CL2013000369A1 (es) | Anticuerpo que se une especificamente a la proteina de activacion fibroblastica (fap); polinucleotido que lo codifica; vector; celula huesped; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar cancer. | |
| CL2013000019A1 (es) | Proteina fijadora de antigeno aislada que fija el factor de crecimiento epidermico fijador de heparina (hg-egf); molecula de acido nucleico que la codifica; vector; celula huesped; metodo de preparacion; composicion farmaceutica que la comprende; y su uso para tratar una enfermedad hiperproliferativa. | |
| BR112013016022A2 (pt) | composto heterocíclico fundido e uso do mesmo para controle de peste. | |
| BRPI0924177A2 (pt) | Polipeptídeos, seu método de preparação, sua composição, sequência de nucleotídeo e uso | |
| ZA200809394B (en) | Rage fusion proteins, formulations, and methods of use thereof | |
| DK3168229T3 (da) | Fremstilling af proteiner og polypeptider. | |
| BRPI0819299A2 (pt) | Uso de composição, e, composição contendo proteína | |
| CL2014003112A1 (es) | Célula bacteriana gram-negativa recombinante que comprende un gen spr mutante y un gen capaz de expresar o sobreexpresar proteínas capaces de facilitar el plegamiento de proteínas; y método para producir proteínas de interés. |